BioGenCell has developed a long-term road map for the next five years and beyond.
Our goal is to reach commercialization of the first product based on FDA’s and EMA’s expedited programs while developing a pipeline of additional products based on our technology platform.
A phase I/II multi-centered randomized-controlled-study in 40 patients was approved in Israel and in Belgium. This will be followed by a pivotal phase III study.
A market leading position in bringing stem cell treatments to patients in every clinic will be achieved due to the technology’s superior safety and scalability. BioGenCell will add value and open a competitive gap by creating a revenue stream based on FDA’s and EMA’s expedited programs. By the end of the clinical trials, the company will have developed strategic partnerships and distribution channels.
- Home
- About
- VISIT ISRAEL
- Faculty
- PROGRAM
- Scientific Program
- GUIDELINES FOR ORAL PRESENTATION
- Satellite Symposia Sessions
- Abstract Submission
- Get Published in JACC: CV Interventions
- Complex coronary and Valve cases
- The israeli medtech workshop
- Academy of Innovation
- Meet the VC’s – Funding the future of health
- MedTech CEO-Only Forum
- Digital health day
- Supporting Partners
- Sponsorship
- Podcasts
- Startup compettion
- REGISTER NOW
- INVITATION LETTER
